Global Biotechnology Market
Description
Global Biotechnology Market size was valued at USD 1,839.0 billion in 2023 and is poised to grow from USD 2,163.53 billion in 2024 to USD 6,644.23 billion by 2032, growing at a CAGR of 15.0% during the forecast period (2024–2032).
The global biotechnology market is undergoing rapid and transformative growth, propelled by breakthroughs in genetic engineering, molecular biology, and bioprocessing technologies. Surging applications across medical, agricultural, industrial, environmental, and marine biotechnology are driving expansion, with innovations like gene therapies, CRISPR technology, monoclonal antibodies, and regenerative medicine reshaping industries.
Medical biotechnology dominates the segment, fueled by rising chronic disease prevalence, the aging global population, and demand for targeted and personalized treatments. The field is witnessing strong growth in cell and gene therapies—with the FDA anticipating up to 20 approvals per year—alongside the expansion of biologics and mRNA-based platforms. Agricultural biotechnology is being revolutionized through genetically modified crops enhancing yield, pest resistance, and climate resilience, crucial for global food security.
Technological front-runners such as tissue engineering and regeneration and nanobiotechnology are expected to record the highest CAGRs, finding uses in regenerative medicine, targeted drug delivery, and advanced diagnostics. Investments in synthetic biology, bioprinting, microbiome therapeutics, and exosome-based drug delivery are emerging as top growth opportunities.
The Asia-Pacific market is projected to grow fastest, driven by policy support, biotech infrastructure development, and booming pharmaceutical manufacturing in China, India, and Japan. North America maintains market leadership owing to its advanced R&D ecosystem, supportive regulation (e.g., FDA fast-track approvals), and concentration of biotech giants. Europe sustains strong growth through sustainable agriculture initiatives, precision medicine uptake, and high venture capital investment levels.
Key market drivers include rising R&D investments (global biopharma R&D reached USD 72B in 2023), strategic public-private partnerships, rapid adoption of AI and Big Data in drug discovery, and expanding cross-border collaborations. However, challenges persist from high development costs, complex and diverse regulatory frameworks, and lengthy product approval timelines.
The competitive landscape features leaders like Amgen, Johnson & Johnson, Gilead Sciences, Bristol Myers Squibb, Vertex Pharmaceuticals, Roche, Regeneron, Moderna, Biogen, Thermo Fisher Scientific, Pfizer, Bayer AG, and Merck KGaA, alongside rising players in niche biotech domains.
The global biotechnology market is undergoing rapid and transformative growth, propelled by breakthroughs in genetic engineering, molecular biology, and bioprocessing technologies. Surging applications across medical, agricultural, industrial, environmental, and marine biotechnology are driving expansion, with innovations like gene therapies, CRISPR technology, monoclonal antibodies, and regenerative medicine reshaping industries.
Medical biotechnology dominates the segment, fueled by rising chronic disease prevalence, the aging global population, and demand for targeted and personalized treatments. The field is witnessing strong growth in cell and gene therapies—with the FDA anticipating up to 20 approvals per year—alongside the expansion of biologics and mRNA-based platforms. Agricultural biotechnology is being revolutionized through genetically modified crops enhancing yield, pest resistance, and climate resilience, crucial for global food security.
Technological front-runners such as tissue engineering and regeneration and nanobiotechnology are expected to record the highest CAGRs, finding uses in regenerative medicine, targeted drug delivery, and advanced diagnostics. Investments in synthetic biology, bioprinting, microbiome therapeutics, and exosome-based drug delivery are emerging as top growth opportunities.
The Asia-Pacific market is projected to grow fastest, driven by policy support, biotech infrastructure development, and booming pharmaceutical manufacturing in China, India, and Japan. North America maintains market leadership owing to its advanced R&D ecosystem, supportive regulation (e.g., FDA fast-track approvals), and concentration of biotech giants. Europe sustains strong growth through sustainable agriculture initiatives, precision medicine uptake, and high venture capital investment levels.
Key market drivers include rising R&D investments (global biopharma R&D reached USD 72B in 2023), strategic public-private partnerships, rapid adoption of AI and Big Data in drug discovery, and expanding cross-border collaborations. However, challenges persist from high development costs, complex and diverse regulatory frameworks, and lengthy product approval timelines.
The competitive landscape features leaders like Amgen, Johnson & Johnson, Gilead Sciences, Bristol Myers Squibb, Vertex Pharmaceuticals, Roche, Regeneron, Moderna, Biogen, Thermo Fisher Scientific, Pfizer, Bayer AG, and Merck KGaA, alongside rising players in niche biotech domains.
Table of Contents
360 Pages
- 1. Introduction
- 1.1. Objectives of the Study
- 1.2. Scope of the Report
- 1.3. Definitions
- 2. Research Methodology
- 2.1. Information Procurement
- 2.2. Secondary & Primary Data Methods
- 2.3. Market Size Estimation
- 2.4. Market Assumptions & Limitations
- 3. Executive Summary
- 3.1. Global Market Outlook
- 3.2. Segmental Opportunity Analysis
- 3.3. Supply & Demand Trend Analysis
- 4. Market Dynamics & Outlook
- 4.1. Market Overview
- 4.2. Drivers & Opportunities
- 4.3. Restraints & Challenges
- 4.4. Supply & Demand Trends
- 4.5. Porter’s Analysis
- 4.5.1. Competitive Rivalry
- 4.5.2. Threat of Substitutes
- 4.5.3. Bargaining Power of Buyers
- 4.5.4. Threat of New Entrants
- 4.5.5. Bargaining Power of Suppliers
- 5. Key Market Insights
- 5.1. Key Success Factors
- 5.2. Degree of Competition
- 5.3. Top Investment Pockets
- 5.4. Market Attractiveness Index
- 5.5. Evolution of Biotechnology
- 5.6. Regulatory Analysis
- 5.7. Technology Analysis
- 5.8. Market Ecosystem
- 5.9. Value Chain Analysis
- 5.10. PESTEL Analysis
- 5.11. Patent Analysis
- 5.12. Case Study Analysis
- 5.13. Macroeconomic Indicators
- 5.14. Customer & Buying Criteria Analysis
- 6. Global Biotechnology Market Size by Type (2019–2032)
- 6.1. Red Biotechnology
- 6.2. Green Biotechnology
- 6.3. White Biotechnology
- 6.4. Blue Biotechnology
- 6.5. Others
- 7. Global Biotechnology Market Size by Technology (2019–2032)
- 7.1. Nano Biotechnology
- 7.2. PCR Technology
- 7.3. DNA Sequencing
- 7.4. Chromatography
- 7.5. Tissue Engineering & Regeneration
- 7.6. Cell-Based Assays
- 7.7. Fermentation
- 7.8. Others
- 8. Global Biotechnology Market Size by Application (2019–2032)
- 8.1. Medical Biotechnology
- 8.2. Agricultural Biotechnology
- 8.3. Industrial Biotechnology
- 8.4. Environmental Biotechnology
- 8.5. Marine Biotechnology
- 8.6. Bioinformatics
- 8.7. Others
- 9. Global Biotechnology Market Size by End User (2019–2032)
- 9.1. Pharmaceutical & Biotechnology Companies
- 9.2. Contract Research Organizations
- 9.3. Academic & Research Institutes
- 9.4. Others
- 10. Global Biotechnology Market Size by Region (2019–2032)
- 10.1. North America (U.S., Canada)
- 10.2. Europe (UK, Germany, France, Italy, Spain, Rest of Europe)
- 10.3. Asia-Pacific (China, India, Japan, South Korea, Rest of APAC)
- 10.4. Latin America (Brazil, Mexico, Rest of LATAM)
- 10.5. Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
- 11. Competitive Intelligence
- 11.1. Top 5 Player Comparison
- 11.2. Market Positioning of Key Players, 2024
- 11.3. Strategies Adopted by Key Market Players
- 11.4. Recent Developments in the Market
- 11.5. Company Market Share Analysis, 2024
- 12. Company Profiles
- 12.1. Novo Nordisk
- 12.2. Amgen
- 12.3. Johnson & Johnson
- 12.4. Gilead Sciences
- 12.5. Bristol Myers Squibb
- 12.6. Vertex Pharmaceuticals
- 12.7. Roche
- 12.8. Regeneron
- 12.9. Moderna Inc.
- 12.10. Biogen Inc.
- 12.11. Thermo Fisher Scientific Inc.
- 12.12. Pfizer Inc.
- 12.13. Corteva Agriscience
- 12.14. Sanofi
- 12.15. Bayer AG
- 12.16. Merck KGaA
- 12.17. Bluebird Bio Inc.
- 12.18. AbbVie Inc.
- 12.19. Syngenta Group
- 12.20. CSL Limited
- 13. Conclusion & Recommendations
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
